hematologic malignancies
Conditions
Interventions
Experimental group:Autologous hemapoietic stem cell transplantation combined with the infusion of haploidentical granulocyte-colony stimulating factor mobilized peripheral blood stem cells
Control group:Autologous hemapoietic stem cell transplantation
Sponsors
Department of Hematology, Xinqiao Hospital, Third Military Medical University, Chongqing, China.
Eligibility
Sex/Gender
All
Age
No minimum to 60 Years
Inclusion criteria
Inclusion criteria: 1. Patients with hematologic malignancies with medium-high risk who achieved over PR after three cycle chemotherapy; 2. Male or Female; Aged <60 years; 3. KPS is over 60 and survival is over three months; 4. No serious systemic organ dysfunction and ECOG performance status of <=2 at study entry; 5. Understand and voluntarily sign an informed consent.
Exclusion criteria
Exclusion criteria: 1. Serious systemic organ dysfunction; 2. Patient with malignant tumor that needs to be treat; 3. The patients with clinical symptom of brain dysfunction or serious psychiosis that can't understand or obey the study; 4. Patients that can't followed up as scheduled; 5. Patients that can't guarantee complete the plan and follow up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| disease-Free survival;Rate of relapse;Time of hematopoietic recovery;Rate of GVHD;Donor chimerism; | — |
Countries
China
Contacts
Public ContactCheng Zhang
Department of Hematology, Xinqiao Hospital, Third Military Medical University
Outcome results
None listed